Shares of the direct-to-consumer telehealth company Hims & Hers have been halved over the past six months, trading near $27. Investors are now weighing whether the steep sell-off presents a buying opportunity or signals deeper troubles ahead.
While OceanFirst Financial (OCFC) has kept pace with the market, analysts highlight concerns over its weak net interest income growth, modest earnings expansion, and a projected decline in tangible book value. The search for value shifts focus elsewhere.
While LKQ's stock has mirrored the broader market's gains, a deeper look at its core fundamentals reveals concerning trends in organic revenue, cash flow stability, and returns on capital, prompting some investors to seek growth elsewhere.
Fulton Financial (FULT) shares have surged 16% in six months, outpacing the S&P 500. While the rally is impressive, a closer look at its fundamentals reveals potential headwinds in revenue growth, profitability, and book value expansion, prompting some analysts to suggest investors consider rotating capital elsewhere.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
The alternative investment manager faces heightened scrutiny as analysts project a slowdown in revenue growth ahead of Tuesday's earnings release, despite a history of recent beats.
Honda Motor posted a 4.3% year-on-year increase in global vehicle production for December 2025, recovering from a steep November slump. However, the automaker's full-year 2025 output fell nearly 9%, highlighting uneven regional performance with North America rebounding sharply while Asia, particularly China, saw significant declines.
In a landmark move to end regulatory ambiguity, the SEC and CFTC have formally merged their 'Project Crypto' into a single rulebook. The joint initiative aims to harmonize federal oversight of crypto markets, drawing clearer lines between securities and commodities as legislative efforts advance in Congress.
As Zurn Elkay Water Solutions prepares to report its quarterly results, investors are watching to see if the company can extend its impressive track record of exceeding revenue forecasts. We break down the key figures, peer performance, and market sentiment heading into the announcement.
In a bid to boost the global competitiveness of Indian accounting and advisory firms, the government has announced a dual-pronged reform: simplifying the 'accountant' definition under Safe Harbour Rules and merging tax computation standards with financial reporting norms.
As global markets navigate a period of uncertainty, a select group of technology companies across Norway, Sweden, and Israel are posting explosive growth. We examine the financials and strategies behind Appear ASA, Hacksaw AB, and NextVision Stabilized Systems—firms turning innovation into investor returns.
Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.
Amidst a cautious market climate, companies with substantial insider ownership often signal strong internal conviction. We examine three such firms—spanning South Korean tourism, Chinese sensors, and Taiwanese biopharma—where executives and directors have significant skin in the game.
Amidst market volatility and economic crosscurrents, income-focused investors are revisiting dividend stocks for potential stability and yield. We examine three Japanese companies offering yields from 3.3% to 6.3%, analyzing their sustainability and strategic outlook.
While Italtile's stock saw an 11% bump last month, a look at the past five years reveals a sobering picture for long-term investors, with total shareholder returns deep in negative territory even as company earnings grew.
The traditional rulebook for dining during economic stress is obsolete. As a K-shaped recovery widens the gap between income groups, fast-food giants are struggling with deep discounts while casual dining chains unexpectedly thrive by redefining value.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
In a market where Wall Street analysts often shy away from bearish calls, stark price targets on certain stocks raise red flags. We spotlight one contrarian pick and two companies facing significant headwinds.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
As several stocks test their 52-week highs, we separate resilient momentum from potential mirages. We analyze one company capitalizing on long-term trends and two where caution may be warranted.
